PVLA (Palvella Therapeutics) Non Operating Income: $-0.55 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PVLA Palvella Therapeutics Inc PVLA
14 GF Score
Price $152.15
! 2 Warning Signs
View Full Analysis

What is Palvella Therapeutics Non Operating Income?

Palvella Therapeutics PVLA +1.18% 14 Non Operating Income is $-0.55 Mil as of Jun. 2026. GuruFocus rates PVLA with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Palvella Therapeutics's Non Operating Income for the three months ended in Jun. 2026 was $-0.12 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.55 Mil.

Palvella Therapeutics Non Operating Income Related Terms

Palvella Therapeutics Non Operating Income Historical Data

* Premium members only.

The historical data trend for Palvella Therapeutics's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palvella Therapeutics Non Operating Income Chart

Palvella Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Non Operating Income
-0.17 24.30 0.34 0.12

Palvella Therapeutics Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 -0.29 -0.19 0.05 -0.12
PVLA
14GF Score
Palvella Therapeutics Inc PVLA
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Palvella Therapeutics Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $-0.55 Mil mean?
Palvella Therapeutics (PVLA) has a Non Operating Income of $-0.55 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Palvella Therapeutics and its competitors.
Is Palvella Therapeutics' Non Operating Income too high?
Palvella Therapeutics' current Non Operating Income is $-0.55 Mil. Overall, Palvella Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Palvella Therapeutics' Non Operating Income compare to AUPH and URGN?
Palvella Therapeutics' Non Operating Income of $-0.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Palvella Therapeutics and its competitors. Palvella Therapeutics's current Non Operating Income is $-0.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palvella Therapeutics stock overvalued right now?
Palvella Therapeutics (PVLA) has a current Non Operating Income of $-0.55 Mil. The current Non Operating Income is $-0.55 Mil. Palvella Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Palvella Therapeutics (PVLA), the current Non Operating Income is $-0.55 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Palvella Therapeutics Business Description

Other Exchanges PI6:Germany
Address 353 W. Lancaster Avenue, Suite 200, Wayne, PA, USA, 19087
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
14GF Score

Get the complete analysis for PVLA

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$152.15
Price